Angiopoietin-Like Protein 4 is Differentially Regulated by Glucocorticoids and Insulin in vitro and in vivo in Healthy Humans

Abstract

Objective:

Angiopoietin-like protein 4 (Angptl4) is a circulating inhibitor of plasma triglyceride clearance via inhibition of lipoprotein lipase. The aim of the present study was to examine the regulation of Angptl4 by glucocorticoids and insulin in vivo in humans, since these factors regulate Angptl4 expression in vitro.

Research design and methods:

In a randomized, placebo-controlled, double-blind, dose-response intervention study, 32 healthy males (age: 22±3 years; BMI 22.4±1.7 kg m^− 2) were allocated to prednisolone 30 mg once daily (n=12), prednisolone 7.5 mg once daily (n=12), or placebo (n=8) for 2 weeks. Angptl4 levels and lipid metabolism were measured before and at 2 weeks of treatment, in the fasted state and during a 2-step hyperinsulinemic clamp. Additionally, human hepatoma cells were treated with dexamethasone and/or insulin.

Results:

Compared to placebo, prednisolone treatment tended to lower fasting Angptl4 levels (P=0.073), raised fasting insulin levels (P=0.0004) and decreased fasting nonesterified fatty acid concentrations (NEFA) (P=0.017). Insulin infusion reduced Angptl4 levels by 6% (plasma insulin ~200 pmol/l, P=0.006) and 22% (plasma insulin ~600 pmol/l, P<0.0001), which was attenuated by prednisolone treatment (P=0.03). Prednisolone 7.5 mg and 30 mg dose-dependently decreased insulin-mediated suppression of lipolysis (by 11±5% and 34±6% respectively). Prednisolone 30 mg enhanced fasting triglyceride levels (P=0.028). Plasma Angptl4 was not related to prednisolone-induced changes in lipid metabolism. In human hepatoma cells, dexamethasone increased Angptl4 mRNA expression and protein secretion, whereas insulin had the opposite effect.

Conclusions:

Insulin lowers plasma Angptl4 levels in humans by lowering NEFA and by inhibiting Angptl4 expression and release. Glucocorticoids counteract insulin-mediated suppression of Angptl4.

Key words

angiopoietin-like protein 4 - glucocorticoids - insulin - prednisolone

*

^* Both authors had equal contributions.

• References

• 1 Staiger H, Haas C, Machann J et al. Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans. Diabetes 2009; 58: 579-589
• 2 Lichtenstein L, Kersten S. Modulation of plasma TG lipolysis by Angiopoietin-like proteins and GPIHBP1. Biochim Biophys Acta 2010; 1801: 415-420
• 3 Kersten S, Lichtenstein L, Steenbergen E et al. Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler Thromb Vasc Biol 2009; 29: 969-974
• 4 Xu A, Lam MC, Chan KW et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci USA 2005; 102: 6086-6091
• 5 Koster A, Chao YB, Mosior M et al. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 2005; 146: 4943-4950
• 6 Mandard S, Zandbergen F, van Straten E et al. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J Biol Chem 2006; 281: 934-944
• 7 Yoshida K, Shimizugawa T, Ono M et al. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J Lipid Res 2002; 43: 1770-1772
• 8 Romeo S, Pennacchio LA, Fu Y et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 2007; 39: 513-516
• 9 Sanderson LM, Degenhardt T, Koppen A et al. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver. Mol Cell Biol 2009; 29: 6257-6267
• 10 Georgiadi A, Lichtenstein L, Degenhardt T et al. Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress. Circ Res 2010; 106: 1712-1721
• 11 Kersten S, Mandard S, Tan NS et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 2000; 275: 28488-28493
• 12 Yoon JC, Chickering TW, Rosen ED et al. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol Cell Biol 2000; 20: 5343-5349
• 13 Mandard S, Zandbergen F, Tan NS et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem 2004; 279: 34411-34420
• 14 Yamada T, Ozaki N, Kato Y et al. Insulin downregulates angiopoietin-like protein 4 mRNA in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2006; 347: 1138-1144
• 15 Koliwad SK, Kuo T, Shipp LE et al. Angiopoietin-like 4 (ANGPTL4, fasting-induced adipose factor) is a direct glucocorticoid receptor target and participates in glucocorticoid-regulated triglyceride metabolism. J Biol Chem 2009; 284: 25593-25601
• 16 van Raalte DH, Brands M, van der Zijl NJ et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia 2011;
• 17 Ackermans MT, Ruiter AF, Endert E. Determination of glycerol concentrations and glycerol isotopic enrichments in human plasma by gas chromatography/mass spectrometry. Anal Biochem 1998; 258: 80-86
• 18 Ackermans MT, Pereira Arias AM, Bisschop PH et al. The quantification of gluconeogenesis in healthy men by (2)H2O and [2-(13)C]glycerol yields different results: rates of gluconeogenesis in healthy men measured with (2)H2O are higher than those measured with [2-(13)C]glycerol. J Clin Endocrinol Metab 2001; 86: 2220-2226
• 19 Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 1987; 36: 914-924
• 20 Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 1959; 82: 420-430
• 21 Smart-Halajko MC, Robciuc MR, Cooper JA et al. The relationship between plasma angiopoietin-like protein 4 levels, angiopoietin-like protein 4 genotype, and coronary heart disease risk. Arterioscler Thromb Vasc Biol 2010; 30: 2277-2282
• 22 Robciuc MR, Tahvanainen E, Jauhiainen M et al. Quantitation of serum angiopoietin-like proteins 3 and 4 in a Finnish population sample. J Lipid Res 2010; 51: 824-831
• 23 Ottosson M, Vikman-Adolfsson K, Enerback S et al. The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1994; 79: 820-825
• 24 Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 2009; 297: E271-E288
• 25 Bergo M, Wu G, Ruge T et al. Down-regulation of adipose tissue lipoprotein lipase during fasting requires that a gene, separate from the lipase gene, is switched on. J Biol Chem 2002; 277: 11927-11932